Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miransertib Combinations in Advanced Solid Tumors
NCT02476955Phase 1Terminated
- Start
- Jun 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of miransertib in solid tumor, ovarian cancer and endometrial cancer (EC) (3 arms). Primary endpoints: Treatment Emergent Adverse Events, Overall Response Rate and 2 more. Started Jun 2015; status: terminated.
02
Drugs
miransertib
03
Conditions
solid tumorovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT02476955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476955.